Johnson & Johnson revenue by segment JNJ

Johnson & Johnson splits its revenue into 2 lines in its filings. The largest line in Q3 of fiscal 2026, the quarter ended Sep 27, 2026 was Innovative Medicine at $16.8 billion, 66% of the total.

USD in millions. The percent under a figure is the change from the same quarter a year earlier.

Line
TTM
Sep 27, 2026
Q3 FY2026
Sep 27, 2026
Q2 FY2026
Jun 28, 2026
Q1 FY2026
Mar 29, 2026
Q4 FY2025
Dec 28, 2025
Q3 FY2025
Sep 28, 2025
Q2 FY2025
Jun 29, 2025
Q1 FY2025
Mar 30, 2025
Q4 FY2024
Dec 29, 2024
Revenue
99,335
25,399
25,310
24,062
24,564
23,993
23,743
21,893
22,520
Innovative Medicine
64,330
+9.1%
share 64.8%
16,757
+7.7%
share 66.0%
16,384
+7.8%
share 64.7%
15,426
+11.2%
share 64.1%
15,763
+10.0%
share 64.2%
15,563
share 64.9%
15,202
share 64.0%
13,873
share 63.4%
14,332
share 63.6%
Med Tech
35,005
+5.5%
share 35.2%
8,642
+2.5%
share 34.0%
8,926
+4.5%
share 35.3%
8,636
+7.7%
share 35.9%
8,801
+7.5%
share 35.8%
8,430
share 35.1%
8,541
share 36.0%
8,020
share 36.6%
8,188
share 36.4%
How these figures are calculated

Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
JNJ (NYSE)
Fiscal year ends
January 3
Incorporated in
NJ
Headquarters
New Brunswick, NJ
SEC filer status
Large accelerated filer
SEC CIK
200406
Former names
JOHNSON & JOHNSON ET AL (until Jan 23, 1996)

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.